Global menu

Our global pages


Eversheds advises CBPE Capital on £225 million sale

  • United Kingdom


    Law firm Eversheds has advisedCBPE Capital LLP, the mid-market private equity firm, on the sale of IDIS GroupHoldings to Clinigen Group plc.

    CBPE Capital LLP (CBPE), has sold IDIS GroupHoldings (IDIS) to Clinigen Group plc (Clinigen), the AIM listed specialitypharmaceuticals and pharmaceuticals services business, for an Enterprise Valueof £225m.

    The transaction represents a money multipleof 22x CBPE’s £9.4m investment in Idis.

    IDIS is the global leader in providingregulatory and ethically compliant access to unlicensed medicines forhealthcare professionals and their patients with unmet medical needs.

    The Eversheds team was led by Partner andhead of private equity Richard Moulton, assisted by Principal Associate LouiseFinnie and Associate Andy Lord. Share options advice was provided byPartner Danny Blum and Associate Richard Sharman.

    Richard Moulton said:

    “As the private equity industry becomes increasingly buoyant, we arepleased to have assisted CBPE on this significant deal which is in line withits overall strategy. We look forward to working with the team on futuretransactions.”

    Sean Dinnen of CBPE said:

    “The Eversheds team have provided first class support to CBPEthroughout the period of our investment in Idis. The firm originated theopportunity for us, have given full service support to the IDIS groupthroughout our tenure and have done an excellent job in helping us successfullyexecute this transaction.”


    This information is for guidance purposes only and should not be regarded as a substitute for taking legal advice. Please refer to the full terms and conditions on our website.

    < Go back

    Print Friendly and PDF
    Register to receive regular updates via email.